Literature DB >> 17614827

Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism.

Jose Luís Lobo, David Jiménez, M Teresa Orue, Enric Grau, Dolores Naufall, Olga Madridano, Manuel Monreal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17614827     DOI： 10.1111/j.1365-2141.2007.06679.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.

Authors:  Ariela L Marshall; Federico Campigotto; Donna Neuberg; Betty Rowe; Jean M Connors
Journal:  Clin Appl Thromb Hemost       Date:  2015-04-07       Impact factor: 2.389

2.  Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.

Authors:  Antonio J Carcas; Alberto M Borobia; Marta Velasco; Francisco Abad-Santos; Manuel Quintana Díaz; Carmen Fernández-Capitán; Nuria Ruiz-Giménez; Olga Madridano; Pilar Llamas Sillero
Journal:  Trials       Date:  2012-12-13       Impact factor: 2.279

3.  Warfarin Failure in a Patient With Chronic Thromboembolic Pulmonary Hypertension: A Case Report and Literature Review.

Authors:  Tsering Dolkar; Aysham Chaudry; Ferdous Salauddin; Nway Nway; Nevil Kadakia; Madhumati Kalavar; Muhammad H Dogar
Journal:  Cureus       Date:  2022-07-19

Review 4.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17

Review 5.  Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.

Authors:  Truman J Milling; Alex C Spyropoulos
Journal:  Am J Med       Date:  2016-08-26       Impact factor: 4.965

Review 6.  Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed.

Authors:  Truman J Milling; Alex C Spyropoulos
Journal:  Am J Emerg Med       Date:  2016-09-28       Impact factor: 2.469
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.